Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Cwm LLC

CWM LLC lifted its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 1,037.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,236 shares of the company's stock after purchasing an additional 24,841 shares during the period. CWM LLC's holdings in Verve Therapeutics were worth $124,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in VERV. HighTower Advisors LLC acquired a new position in Verve Therapeutics during the 4th quarter worth approximately $115,000. Commonwealth Equity Services LLC increased its position in Verve Therapeutics by 17.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 31,952 shares of the company's stock worth $180,000 after purchasing an additional 4,785 shares during the period. Teacher Retirement System of Texas increased its position in Verve Therapeutics by 37.4% during the 4th quarter. Teacher Retirement System of Texas now owns 20,254 shares of the company's stock worth $114,000 after purchasing an additional 5,512 shares during the period. American Century Companies Inc. increased its position in Verve Therapeutics by 12.3% during the 4th quarter. American Century Companies Inc. now owns 127,464 shares of the company's stock worth $719,000 after purchasing an additional 13,916 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in Verve Therapeutics during the 4th quarter worth approximately $101,000. Institutional investors and hedge funds own 97.11% of the company's stock.

Verve Therapeutics Stock Performance

Shares of VERV stock remained flat at $11.13 on Friday. The firm has a market capitalization of $992.13 million, a PE ratio of -5.27 and a beta of 2.23. The company's 50-day simple moving average is $9.30 and its 200-day simple moving average is $7.00. Verve Therapeutics, Inc. has a twelve month low of $2.86 and a twelve month high of $11.40.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%. The firm had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. On average, equities research analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Analyst Upgrades and Downgrades

VERV has been the topic of several recent analyst reports. Canaccord Genuity Group cut Verve Therapeutics from a "strong-buy" rating to a "hold" rating and dropped their target price for the stock from $39.00 to $13.00 in a research report on Tuesday, June 17th. HC Wainwright lowered Verve Therapeutics from a "buy" rating to a "neutral" rating and set a $13.50 price target on the stock. in a research note on Wednesday, June 18th. Wall Street Zen raised Verve Therapeutics to a "hold" rating in a research note on Saturday, July 26th. Jefferies Financial Group lowered Verve Therapeutics from a "buy" rating to a "hold" rating and reduced their target price for the company from $28.00 to $11.00 in a research note on Wednesday, June 18th. Finally, Lifesci Capital lowered Verve Therapeutics from a "strong-buy" rating to a "hold" rating and set a $12.00 target price on the stock. in a research note on Wednesday, June 18th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $14.57.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.